Compare HubSpot Inc (HUBS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Twist Bioscience Corp — how do they compare? HubSpot Inc trades at $228.35 (market cap $11.56B), while Twist Bioscience Corp trades at $163.14 (market cap $10.08B). The key difference: HubSpot Inc and Twist Bioscience Corp are close in size by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Twist Bioscience Corp for 27 Days on average.
| HUBS | TWST | |
|---|---|---|
Market Cap | $11.56B | $10.08B |
Volume | 1,891,287 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $494.58 | $205.00 |
52-Week Low | $170.39 | $25.45 |
Typical Hold Time | 78 Days | 27 Days |
Enterprise Value | $10.46B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $233.94, up 6.19% today, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $3.26, beating estimates of $3.02, continuing a trend of positive surprises. Revenue growth is robust, with 2025 revenue at $3.13 billion, and net income turning positive at $45.91 million. Analyst sentiment remains largely positive with a consensus price target of $243.65, though valuation multiples like a P/E of 82.51 are elevated. Recent news highlights AI strategy advancements and partnerships, including a deepened collaboration with OpenAI.
The outlook for HUBS is cautiously optimistic, driven by strong revenue growth, margin expansion potential, and strategic AI initiatives. Key risks include high valuation multiples, competitive pressures in the CRM space, and potential demand headwinds from economic conditions. Institutional ownership trends show significant interest, such as the California State Teachers Retirement System increasing its stake. The stock presents a growth opportunity but requires monitoring of execution risks and market sentiment shifts.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
